The world's first oral targeted therapy for HER2 mutation late-stage non-small cell lung cancer has been approved in China.

Today, Boehringer Ingelheim and BeiGene jointly announced that the popularent biotine tablets they jointly promote in mainland China have been officially approved by the Chinese Drug Administration for the treatment of adult patients with unresectable locally advanced or metastatic non-small cell lung cancer with HER2 activating mutations who have received at least one past systemic therapy. This drug is also the world's first and currently the only approved oral HER2 tyrosine kinase inhibitor.